Vaccination for malignant melanoma: Recent developments

Oncology

Volumn 60, Issue 1, 2001, Pages 1-7

  Jäger, Dirk ^a   Jäger, Elke ^a   Knuth, Alexander ^a  

^a KRANKENHAUS NORDWEST   (Germany)

Author keywords

CD8+ T cell response; Immunoselection; Tumor antigens

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PEPTIDE DERIVATIVE; TUMOR ANTIGEN; VIRUS ANTIGEN;

ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELLULAR IMMUNITY; DENDRITIC CELL; HUMAN; HUMORAL IMMUNITY; MELANOMA; POINT MUTATION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR RECURRENCE; TUMOR REGRESSION; VACCINATION;

ANTIGENS, CD8; ANTIGENS, NEOPLASM; ANTIGENS, VIRAL; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOTHERAPY, ACTIVE; MELANOCYTES; MELANOMA; MEMBRANE PROTEINS; POINT MUTATION; PROTEINS; SKIN NEOPLASMS; UP-REGULATION;

EID: 0035165176     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000055289     Document Type: Review

References (57)

1. The regressing thin malignant melanoma: A distinctive lesion with metastatic potential
2. T-cell-mediated cytotoxicity against autologous malignant melanoma: Analysis with interleukin-2-dependent T-cell cultures
3. T cell responses to human malignant tumours
4. Cellular and humoral responses against cancer: Implications for cancer vaccines
5. Direct visualization and phenotypic analysis of virus-specific T lymphocytes in HIV-infected individuals
6. Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses
7. A gene encoding an antigen recognized by cyctolytic T lymphocytes on a human melanoma
8. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma
9. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes
10. Expression of MAGE genes in primary and metastatic cutaneous melanoma
11. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E
12. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
13. Human neoplasms elicit multiple specific immune responses in the autologous host
14. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leucocyte antigen (HLA)-A2-binding peptide epitopes
15. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes
16. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
17. A new gene coding for a differentiation antigen recognized by autologous cytolytic lymphocytes on HLA-A2 melanomas
18. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor
19. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes
20. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating lymphocytes associated with in vivo tumor regression
21. Isolation of naturally processed peptides recognized by cytolytic T lymphocytes (CTL) on human melanoma cells in association with HLA-A2.1
22. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens
23. Granulocyte macrophage colony-stimulation factor enhances immune responses to melanoma-associated peptides in vivo
24. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma
25. CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma
26. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma
27. Oncogenic proteins as tumor antigens
28. Antibodies against p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot
29. Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer
30. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): Implications for the immune control of EBV-positive malignancies
31. HLA-class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release
32. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis
33. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells
34. Characterization of MHC class I restricted cytotoxic T cell responses to tax in HTLV-1 infected patients with neurologic disease
35. Tumor antigens recognized by cytolytic T cells
36. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3
37. Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells
38. Humoral immune responses of cancer patients against 'Cancer-Testis' antigen NY-ESO-1: Correlation with clinical events
39. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection
40. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy
41. Cytolytic T cell reactivity against melanoma-associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals
42. Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma mediated by antigen-specific CTL
43. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1
44. CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells
45. Clonal expansion of Melan A-specific cytotoxic T lymphocytes (CTL) in a melanoma patient responding to continued immunization with melanoma-associated peptides
46. GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells
47. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
48. Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogenously expressed in human melanomas
49. Immunophenotyping of melanomas for tyrosinase: Implications for vaccine development
50. A survey of the humoral immune response of cancer patients to a panel and human tumor antigens
51. Tolerance, danger, and the extended family
52. Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation
53. Hepatitis B virus small surface antigen particles are processed in a novel endosomal pathway for major histocompatibility complex class I-restricted epitope presentation
54. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
55. Influence of interleukin-12 on p53 peptide vaccination against established Meth A sarcoma
56. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: Evidence for immunoselection of antigen-loss variants in vivo